Last updated: June 2, 2026
Arixtra (fondaparinux) Suppliers: Who Manufactures Bulk Drug, API, and Finished Dosage Forms
Arixtra (fondaparinux sodium) supply is concentrated in a small set of contract manufacturers and API production sites. In practice, the active ingredient and finished-dose manufacture sit behind tight licensing controls, with batch release dependent on the named manufacturing sites on the product label and the applicable marketing authorization dossier.
Who supplies Arixtra fondaparinux API and finished product?
Core supply chain (what matters for R&D, licensing, and litigation):
- API (fondaparinux sodium) production: provided by designated API manufacturing sites listed in regulatory submissions and product labeling (commonly shown as “manufactured by” or “manufacturing site” in EU/UK documents and referenced within global dossier content).
- Finished dosage form manufacture: provided by designated sterile/non-sterile injection assembly and packaging sites listed for Arixtra strengths and presentation formats.
What buyers verify in diligence
- Whether the supplier is licensed to manufacture fondaparinux sodium (API) and/or filled syringes/prefilled devices (finished dosage form).
- Whether the manufacturing site is the one referenced in the applicable marketing authorization and validated for commercial scale batches.
- Whether the supplier controls key intermediates and polymorph/impurity profiles consistent with the dossier specification.
Which manufacturing sites are typically listed for Arixtra strengths (how to map supply)
For supply verification, diligence usually crosswalks:
- Product label “manufactured by” entities (EU/UK and country registrations)
- Batch release manufacturer and site responsible for quality (often distinct from the maker)
- Packager (secondary packaging can shift without changing API source)
Which companies supply Arixtra to the US market (FDA-facing manufacturing/quality data)?
The US commercial supply chain is anchored to what the FDA application and labeling identify as:
- Drug substance manufacturer(s)
- Drug product manufacturer(s)
- Batch release and testing sites (frequently shown in drug product quality sections and reflected in manufacturing listings)
For market access, generic and biosimilar developers rely on:
- FDA drug listing data
- DMF referenced sites (for API only)
- Orange Book information (for RLD identification and exclusivity context, not for manufacturing)
Are there multiple Arixtra suppliers across EU, UK, and global distribution?
Yes. Commercial supply typically spans:
- Regional finished-dose manufacturers (often for packaging and device filling)
- Dedicated API sites (less likely to change due to dossier tightness and impurity control)
Practical implication: Even when the brand authorization stays the same, the manufacturing network can be updated via regulatory notification/approval. That creates procurement and IP diligence risk for contract manufacturers offering “equivalent” supply.
How do Arixtra suppliers handle the prefilled syringe or injection device supply chain?
Arixtra is an injectable anticoagulant supplied as prefilled formats. Supplier responsibilities usually include:
- Pre-assembly of the drug product into the specified container closure system
- Filling, inspection, and sealing under validated controls
- Device and labeling integration (where applicable to presentation)
Diligence focus for contract procurement:
- Container closure system compatibility
- Extractables and leachables controls
- Sterility assurance for injection presentations (as applicable)
- Line clearance, contamination control, and batch traceability
What patent and licensing constraints affect who can supply Arixtra?
Supply of fondaparinux is constrained less by a “single supplier” issue and more by:
- Process and intermediate patents protecting manufacturing routes
- Formulation/device patents covering finished-dose characteristics (less prominent for a simple injectable salt, but still present in many injectables)
- Regulatory dossier reliance and data exclusivity structures that affect entry timing for competitors
Commercial procurement risk: A contract manufacturer may be able to make a facsimile, but the supplier cannot legally sell a protected product into the same jurisdiction and indication without overcoming IP constraints or using a licensed route.
Which Arixtra suppliers matter for Paragraph IV and generic entry risks?
Generic developers do not need “brand suppliers,” but they need:
- A DMF-capable API source for fondaparinux sodium
- CMC capacity to manufacture a dosage form that meets bioequivalence and impurity specs
Why supplier matters: If a generic relies on an API supplier that is also a protected source of key intermediates or process steps, there can be:
- IP exposure tied to process claims
- Supply interruption risk if the supplier ties its manufacturing to brand licensing
How does Arixtra supply compare with other anticoagulants (enoxaparin, heparin, rivaroxaban)?
Arixtra (fondaparinux) differs materially in supply dynamics:
- Fondaparinux is manufactured as a defined synthetic anticoagulant with a constrained set of validated routes.
- Heparins and some biosourced anticoagulants often have broader supplier ecosystems because upstream sourcing can vary.
- DOACs like rivaroxaban have different synthesis routes and often wider API supplier options, depending on jurisdiction.
Net effect: Arixtra’s supplier base for API and finished dosage forms is typically narrower and more controlled than many oral anticoagulants.
Key supplier diligence checklist for Arixtra procurement
For API procurement
- Confirm the API is fondaparinux sodium, not a related intermediate or salt form.
- Verify DMF or dossier referencing chain to match commercial specifications.
- Request CoA and batch genealogy from representative lots.
For finished-dose procurement
- Verify the manufacturing site is approved for the specific presentation and strength.
- Confirm device filling and packaging specifications align with the regulatory submission.
- Ensure QA agreements cover deviation handling, change control, and recall cooperation.
Key Takeaways
- Arixtra supply is typically anchored to a limited set of API manufacturing sites and designated finished-dose manufacturing/packaging facilities.
- Contract procurement needs tight mapping to the manufacturing sites named in regulatory and labeling materials, since site changes drive CMC and batch-release risk.
- IP and licensing constraints can limit who can supply “usable” product for specific markets and timelines, affecting availability for generic entrants and downstream partners.
FAQs
- What manufacturing sites appear on Arixtra labels for finished dosage form?
- Which DMF-referenced manufacturers typically produce fondaparinux sodium API for Arixtra?
- How do changes in Arixtra manufacturing sites get approved with regulators?
- What CMC specs most strongly constrain substitution of fondaparinux sodium API between suppliers?
- Do Arixtra supply constraints differ by country (US vs EU/UK) or by presentation strength?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- European Medicines Agency. (n.d.). EPAR documents and product information for fondaparinux-containing medicines. European Medicines Agency.
- Medicines and Healthcare products Regulatory Agency. (n.d.). UK public assessment reports for fondaparinux products. MHRA.
